📷 Image: Wikimedia Commons / MRNA Photographer
Business
MRNA Shares Surge to New 52‑Week Peak as Goldman Upgrades Target Before Melanoma Trial Results
✍️ Asianet Newsable
🗓 16 Oct 2026, 03:37 AM
👁 9
Shares of Moderna (MRNA) climbed to a fresh 52‑week high after Goldman Sachs raised its price target, ahead of the release of melanoma trial data.
Moderna Inc. (MRNA) saw its shares jump to a new 52‑week high on Thursday, rising about 4.5% to close at $140.12.
Goldman Sachs upgraded its price target for the company from $145 to $165, citing optimism over the upcoming melanoma trial data.
The company’s latest data on its mRNA‑based melanoma vaccine, expected to be released later this week, is seen as a potential catalyst for further upside.
The rally was mirrored across the Nasdaq, with other biotech names also gaining momentum as investors weigh the implications of the new data.
Goldman Sachs upgraded its price target for the company from $145 to $165, citing optimism over the upcoming melanoma trial data.
The company’s latest data on its mRNA‑based melanoma vaccine, expected to be released later this week, is seen as a potential catalyst for further upside.
The rally was mirrored across the Nasdaq, with other biotech names also gaining momentum as investors weigh the implications of the new data.